Back to Authors

Zeidner, Joshua F.

https://orcid.org/0000-0002-9014-1514

A5040303721 | I114027177

Mayo Clinic

University of North Carolina at Chapel Hill

Citations 22

Randomized multicenter phase II trial of timed-sequential therapy with flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus “7+3” for adults with newly diagnosed acute myeloid leukemia (AML).

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 7002-7002

10.1200/jco.2014.32.15_suppl.7002

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML

Blood | January 18, 2018 | Volume: 131 | Issue: 13 | Pages: 1415-1424

10.1182/blood-2017-09-805895 | PMID 29348128

Key Points RP2D of PEV 20 mg/m2 in PEV/AZA combo did not alter toxicity profile of AZA; dose-limiting toxicities were transiently elevated AST/ALT. In treatment-naive older AML patients, the intent-to-treat ORR was 50%.